8-K: PepGen Updates DM1 Drug Data, Eyes Best-in-Class Potential

PepGen Inc. updated its corporate presentation, highlighting positive single-dose splicing correction data for PGN-EDODM1 in Myotonic Dystrophy Type 1 and outlining upcoming clinical milestones.

Summary

• PepGen Inc. updated its Corporate Presentation as of March 2026, detailing progress on its lead investigational therapy, PGN-EDODM1.
• PGN-EDODM1 is being developed for Myotonic Dystrophy Type 1 (DM1) and is positioned as a potential best-in-class treatment due to its selective targeting of pathogenic DMPK RNA.
• The therapy has demonstrated a favorable emerging safety profile and achieved the highest splicing correction ever reported in DM1 patients after a single dose.
• Regulatory clearance for the FREEDOM2 study has been received in South Korea, Australia, and New Zealand, with enrollment now open across Canada, UK, and South Korea.
• PGN-EDODM1 holds Orphan Drug & Fast Track Designation in the U.S. and Orphan Drug Designation in the EU.
• Results from the FREEDOM Phase 1 single-ascending dose study showed dose-dependent splicing correction at Day 28: 12.3% at 5 mg/kg, 29.1% at 10 mg/kg, and 53.7% at 15 mg/kg.
• Across all doses in the FREEDOM study, 87.5% of participants showed improved splicing.
• PGN-EDODM1 was generally well-tolerated, with most treatment-emergent adverse events (TEAEs) being mild to moderate.
• A dose-limiting toxicity (DLT) at 15 mg/kg involved a transient decrease in eGFR(cys), which resolved without intervention.
• The FREEDOM2 Phase 2 multiple-ascending dose (MAD) study is currently underway, with dosing complete for the 5 mg/kg cohort and ongoing for the 10 mg/kg cohort.
• The U.S. FDA recently placed a partial clinical hold on the FREEDOM2-DM1 study.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this update positively due to strong efficacy data and a favorable safety profile for PGN-EDODM1, despite the partial clinical hold on the FREEDOM2 study which introduces some uncertainty.

Positives

• PGN-EDODM1 shows best-in-class potential for Myotonic Dystrophy Type 1 (DM1) by selectively targeting pathogenic DMPK RNA.
• Demonstrated the highest splicing correction ever reported in DM1 patients after a single dose, achieving 53.7% correction at 15 mg/kg.
• A favorable emerging safety profile was observed, with most treatment-emergent adverse events (TEAEs) being mild to moderate.
• 87.5% of participants across all doses in the FREEDOM study showed improved splicing.
• Regulatory clearance has been received in South Korea, Australia, and New Zealand, expanding trial enrollment for FREEDOM2.
• PGN-EDODM1 has received Orphan Drug & Fast Track Designation in the U.S. and Orphan Drug Designation in the EU, indicating regulatory support.
• The company's cash runway is expected to extend into the second half of 2027.

Negatives

• The U.S. FDA recently placed a partial clinical hold on the FREEDOM2-DM1 study, which could impact development timelines.
• One dose-limiting toxicity (DLT) at 15 mg/kg involved a transient decrease in eGFR(cys), although it resolved without intervention.
• One drug-related serious adverse event (SAE) of severe abdominal pain at 10 mg/kg was reported, though it was confounded by off-label medication use.

Risks

• Delays or failure to successfully initiate or complete ongoing and planned development activities for product candidates, including PGN-EDODM1.
• Inability to enroll patients in clinical trials, including FREEDOM2.
• Interpretation of clinical and preclinical study results may be incorrect, or anticipated therapeutic activity levels may not be observed in clinical testing, including for PGN-EDODM1.
• Product candidates, including PGN-EDODM1, may not be safe and effective or otherwise demonstrate safety and efficacy in clinical trials.
• Adverse outcomes from regulatory interactions, including delays in regulatory review, clearance to proceed or approval by regulatory authorities, or other regulatory feedback requiring modifications to development programs, such as the release of the partial clinical hold placed by FDA on the FREEDOM2 study.
• Changes in regulatory framework that are out of the company's control.
• Inability to obtain, maintain, and protect intellectual property.
• Inability to enforce patents against infringers and defend the patent portfolio against challenges from third parties.
• Competition from others developing therapies for the indications being pursued.
• Unexpected increases in expenses associated with development activities or other events that adversely impact financial resources and cash runway.
• Dependence on third parties for some or all aspects of product manufacturing, research, and preclinical and clinical testing.

Future Outlook

PepGen anticipates reporting initial clinical results for the 5 mg/kg cohort of the FREEDOM2 study in Q1 2026, followed by results for the 10 mg/kg cohort in H2 2026. The company expects its cash runway to extend into the second half of 2027. There is also potential to extend dosing to the 12.5 mg/kg dose level in the FREEDOM2 study, dependent on recommendations from the Data Safety Monitoring Board (DSMB).

Management Comments

• Our EDO platform has been designed and developed to solve the decades-long problem of efficient oligonucleotide penetration into muscle cells and nuclei.
• PGN-EDODM1 has the potential to offer a best-in-class treatment option for Myotonic Dystrophy Type 1.
• We expect that significant correction of mis-splicing with more doses of PGN-EDODM1 over a longer treatment period could potentially provide improved functional benefit for patients with DM1.

Industry Context

StockSavvy.ai notes that the development of therapies for Myotonic Dystrophy Type 1 (DM1) remains an area of high unmet medical need, with no approved therapies directly addressing the underlying genetic cause of the disease. PepGen's EDO platform, designed to improve nuclear delivery of oligonucleotides, positions it to potentially overcome key limitations faced by prior approaches in the neuromuscular disease space. The reported 'highest splicing correction ever' for PGN-EDODM1, if sustained and translated into functional benefits, could represent a significant advancement in a field where effective treatments are scarce.

Comparison to Industry Standards

• PGN-EDODM1 demonstrated the 'highest splicing correction ever reported in DM1' after a single dose, suggesting a potentially superior efficacy profile compared to other investigational therapies or historical data in the DM1 space.
• The EDO platform's ability to achieve superior nuclear delivery and uptake of therapeutic oligonucleotides is presented as overcoming key limitations of prior approaches, differentiating it from other oligonucleotide delivery methods that may struggle with endosomal escape or target engagement.

Stakeholder Impact

• Shareholders: Potential for increased valuation if PGN-EDODM1 continues to show strong results and progresses through trials, but risk from clinical hold and development delays.
• Patients (DM1): Hope for a potentially best-in-class therapy addressing the underlying cause of Myotonic Dystrophy Type 1, offering significant functional improvement.
• Employees: Continued employment and potential growth opportunities within a company advancing a promising therapeutic candidate.
• Regulatory Authorities: Ongoing engagement and review of clinical data, particularly regarding the partial clinical hold.

Next Steps

• Report initial clinical results for the FREEDOM2 5 mg/kg cohort in Q1 2026.
• Report initial clinical results for the FREEDOM2 10 mg/kg cohort in H2 2026.
• Continue dosing patients in the 10 mg/kg cohort of the FREEDOM2 study.
• Potentially extend dosing to the 12.5 mg/kg dose level in FREEDOM2, dependent on DSMB recommendations.
• Address the partial clinical hold placed by the FDA on the FREEDOM2 study.

Key Dates

Recommendation

While the clinical data for PGN-EDODM1 shows promising efficacy with 'highest ever reported splicing correction' and a generally favorable safety profile, the partial clinical hold by the FDA on the FREEDOM2 study introduces significant uncertainty and potential delays. Investors should hold to monitor the resolution of the clinical hold and subsequent progress of the FREEDOM2 trial before making further investment decisions, as the hold could impact timelines and future capital needs.

Keywords

PepGen, PGN-EDODM1, Myotonic Dystrophy Type 1, DM1, EDO platform, oligonucleotide, clinical trial, FREEDOM study, FREEDOM2 study, splicing correction, neuromuscular disease, Orphan Drug, Fast Track Designation, biotechnology, pharmaceutical, clinical hold